. Author manuscript; available in PMC: 2023 Sep 1.

Published in final edited form as: IEEE Access. 2023 Jul 25;11:84228–84240. doi: 10.1109/access.2023.3298750

TABLE 5.

Gradient Boosting performance for predicting the length of the first treatment using a single drug combination (Ethambutol, Isoniazid, Pyrazinamide, Rifampicin) with different features: Using radiological records for 1296 patients, genomic records for 480 patients, and records with both radiological and genomic information for 411 patients.

Training features	N	Mean Absolute Error (days)	Median Absolute Error (days)	Relative Error (%)
Radiological features	1296	48.7 ±2.1	26.9 ±2.1	27.4 ± 2.4
Genomic features	480	48.2 ± 10.0	17.0 ±3.6	21.2 ±6.2
Radiological features	411	34.1 ±2.5	14.2 ±1.9	17.8 ±3.6
Genomic features	411	37.7 ±5.7	14.1 ± 1.4	19.9 ±5.9
Radiological and Genomic features	411	36.3 ± 5.0	16.1 ±2.4	19.0 ±5.4